Fluorescent probes for proteolysis: Tools for drug discovery

Nature Reviews Drug Discovery

Volumn 3, Issue 1, 2004, Pages 58-69

  Neefjes, Jacques ^a   Dantuma, Nico P ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ANTIRETROVIRUS AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE 8 INHIBITOR; CATHEPSIN S; CELL ENZYME; EPOXOMICIN; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; INDINAVIR; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; LACTONE; LACTONE DERIVATIVE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NELFINAVIR; PRALNACASAN; PRINOMASTAT; PROTEASOME INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; REBIMASTAT; RITONAVIR; SAQUINAVIR; TANOMASTAT; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ARTERIOSCLEROSIS; CARCINOGENESIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG DETERMINATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SUBSTRATE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; STRUCTURE ACTIVITY RELATION; UBIQUITINATION; VIRUS RESISTANCE;

EID: 0347765874     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1282     Document Type: Review

References (128)

1. Jensen, T. J. et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83, 129-135 (1995).
2. Reits, E. A., Vos, J. C., Gromme, M. & Neefjes, J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404, 774-778 (2000).
3. Schubert, U. et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774 (2000).
4. Yewdell, J. W., Anton, L. C. & Bennink, J. R. Defective ribosomal products (DRiPS): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157, 1823-1826 (1996).
5. Sherman, M. Y. & Goldberg, A. L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29, 15-32 (2001).
6. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev. Neurosci. 4, 49-60 (2003).
7. Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425-479 (1998).
8. Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367-380 (1998).
9. Tomkison, B. Tripeptidyl peptidases: enzymes that count. Trends Biochem. Sci. 24, 355-359 (1999).
10. Beninga, J., Rock, K. L. & Goldberg, A. L. Interferon-γ can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273, 18734-18742 (1998).
11. York, I. A. et al. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18, 429-440 (2003).
12. Walsh, P. N. & Ahmad, S. S. Proteases in blood clotting. Essays Biochem. 38, 95-111 (2002).
13. Budihardjo, I., Oliver, H., Lutter, M., Luo, X. & Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15, 269-290 (1999).
14. Brinckerhoff, C. E. & Matrisian, L. M. Matrix metalloproteinases: a tail of a frog that became a prince. Nature Rev. Mol. Cell Biol. 3, 207-214 (2002).
15. Xia, W. & Wolfe, M. S. Intramembrane proteolysis by presenilin and presenilin-like proteases. J Cell Sci. 116, 2839-2844 (2003).
16. Taylor, N. A., Van De Ven, W. J. & Creemers, J. W. Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J. 17, 1215-1227 (2003).
17. Ciechanover, A. & Brundin, P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40, 427-446 (2003).
18. Schwartz, A. L. & Ciechanover, A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 50, 57-74 (1990).
19. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
20. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
21. Pagano, M. & Benmaamar, R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 4. 251-256 (2003).
22. Rock, K. L. & Goldberg, A. L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17, 739-779 (1999).
23. Yewdell, J. W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nature Rev. Immunol. 3, 952-961 (2003).
24. Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663 (2000).
25. LeBlanc, R. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000 (2002).
26. Meng. L. et al. Epoxomicin; a potent and selective proteasome inhibitor, exhibits in vivo antinflammatory activity. Proc. Natl Acad. Sci. USA 96, 10403-10408 (1999).
27. Sunwoo, J. B. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7, 1419-1428 (2001).
28. Schwarz, K. et al. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J. Immunol. 164, 6147-6157 (2000).
29. Paramore, A. & Frantz, S. Bortezomib. Nature Rev. Drug Discov. 2, 611-612 (2003)
30. Aghajanian, C. et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2505-2511 (2002).
31. Andre, P. et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presetation, and T cell responses. Proc. Natl Acad. Sci. USA 95, 13120-13124 (1998).
32. Liang, J. S. et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Med. 7, 1327-1331 (2001).
33. Pati, S. et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99, 3771-3779 (2002)>
34. Pajonk, F., Himmelsbach, J., Riess, K., Sommer, A. & McBride, W. H. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 62, 5230-5235 (2002).
35. Bogyo, M. et al. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HsIV by a new class of inhibitors. Proc. Natl Acad. Sci. USA 94, 6629-6634 (1997).
36. Fenteany, G. et al. Inhibition of proteasome activities and subunits-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731 (1995).
37. Kisselev, A. F. & Goldberg, A. L. Proteasome inhibitors from research tools to drug candidates. Chem. Biol. 8, 739-758 (2001).
38. Thrower, J. S., Hoffman, L., Rechsteiner, M. & Pickart, C. M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102 (2000).
39. Breitschopf, K., Bengal, E., Ziv, T., Admon, A. & Ciechanover, A. A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. EMBO J. 17, 5964-5973 (1998).
40. Bloom, J., Amador, V., Bartolini, F., DeMartino, G. & Pagano, M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 115, 71-82 (2003).
41. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533 (2001).
42. Laney, J. & Hochstrasser, M. Substrate targeting in the ubiquitin system. Cell 97, 427-430 (1999).
43. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W. & Prasher, D. C. Green fluorescent protein as a marker for gene expression. Science 263, 802-805 (1994).
44. Dantuma, N. P., Lindsten, K., Glas, R., Jeline, M. & Masuccie, M. G. Short-lived green fluorescent proteins for quantification of ubiquitin/proteasome-dependent proteolysis in living cells. Nature Biotechnol. 18, 538-543 (2000).
45. Bachmair, A., Finley, D. & Varshavsky, A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234, 179-186 (1986).
46. Johnson, E. S., Ma, P. C., Ota, I. M. & Varshavsky, A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J. Biol. Chem. 270, 17442-17456 (1995).
47. Varshavsky, A. The N-end rule: functions, mysteries, uses. Proc. Natl Acad. Scie USA 93, 12142-12149 (1996).
48. Stack, J. H., Whitney, M., Rodems, S. M. & Pollok, B. A. A ubiquitin-based tagging system for controlled modulation of protein stability. Nature Biotechnol. 18, 1298-1302 (2000).
49. Gilon, T., Chomsky, O. & Kulka, R. G. Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae. EMBO J. 17, 2759-2766 (1998).
50. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).
51. Gilon, T., Chomsky, O. & Kulka, R. G. Degradation signals recognized by the Ubc6p-Ubc7p ubiquitin-conjugating enzyme pair. Mol. Cell. Biol. 20, 7214-7219 (2000).
52. Plemper, R. K. & Wolf, D. H. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem. Sci. 24, 266-270 (1999).
53. Ploegh, H. L. Viral strategies of immune evasion. Science 280, 248-253 (1998).
54. Wiertz, E. J. et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384, 432-438 (1996).
55. Wiertz, E. J. et al. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84, 769-779 (1996).
56. Kessler, B. M. et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic β-subunits. Chem. Biol. 8, 913-929 (2001).
57. Myung, J., Kim, K. B., Lindsten, K., Dantuma, N. P. & Crews, C. M. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol. Cell 7, 411-420 (2001).
58. Lee, D. H. & Goldberg, A. L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397-403 (1998).
59. Friant, S., Meier, K. D. & Riezman, H. Increased ubiquitin-dependent degradation can replace the essential requirement for heat shock protein induction. EMBO J. 22, 3783-3791 (2003).
60. Dantuma, N., Heessen, S., Lindsten, K., Jeline, M. & Masucci, M. G. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc. Natl Acad. Sci. USA 97, 8381-8385 (2000).
61. Verhoef, L. G., Lindsten, K., Masucci, M. G. & Dantuma, N. P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. 11, 2689-2700 (2002).
62. Zoghbi, H. Y. & Orr, H. T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
63. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M. G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl Acad. Sci. USA 94, 12616-12621 (1997).
64. Sharipo, A., Imreh, M., Leonchiks, A., Imreh, S. & Masucci, M. G. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IκBα with the proteasome: a new mechanism for selective inhibition of proteolysis. Nature Med. 4, 939-944 (1998).
65. Cummings, C. J. et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
66. Dantuma, N. P. & Masucci, M. g. Stabilization signals: a novel regulatory mechanism in the ubiquitin/proteasome system. FEBS Lett. 529, 22-26 (2002).
67. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 407, 313-319 (1997).
68. Hadjantonakis, A. K. & Nagy, A. The color of mice: in the light of GFP-variant reporters. Histochem. Cell Biol. 115, 49-58 (2001).
69. Huang, W. Y., Aramburu, J., Douglas, P. S. & Izumo, S. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nature Med. 6, 482-483 (2000).
70. Lindsten, K., Menendez-Benito, V., Masucci, M. G. & Dantuma, N. P. A transgenic mouse model of the ubiquitin/proteasome system. Nature Biotechnol. 21, 897-902 (2003).
71. Luker, G. D., Pica, C. M., Song, J., Luker, K. E. & Piwnica-Worms, D. Imaging 26S proteasome activity and inhibition in living mice. Nature Med. 9, 969-973 (2003).
72. Hernández, F., Diaz-Hernández, M., Avila, J. & Lucas, J. J. Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. Trends Neurosci. (in the press).
73. Petrucelli, L. et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007-1019 (2002).
74. Lindsten, K. et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 157, 417-427 (2002).
75. Lindsten, K. & Dantuma, N. P. Monitoring the ubiquitin/proteasome system in conformational diseases. Ageing Res. Rev. 2, 433-449 (2003).
76. Rubinsztein, D. C. Lessons from animal models of Hungtington's disease. Trends Genet. 18, 202-209 (2002).
77. Wong, P. C., Cai, H., Borchelt, D. R. & Price, D. L. Genetically engineered mouse models of neurodegenerative diseases. Nature Neurosci. 5, 633-639 (2002).
78. Michalik, A. & Van Broeckhoven, C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum. Mol. Genet. 12, R173-186 (2003).
79. Jares-Erijman, E. A. & Jovin, T. M. FRET imaging. Nature Biotechnol. 21, 1387-1395 (2003).
80. Reits, E. et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18, 97-108 (2003).
81. Honey, K. & Rudensky, A. Y. Lysosomal cysteine proteases regulate antigen presentation. Nature Rev. Immunol. 3, 472-482 (2003).
82. Desnick, R. J. & Schuchman, E. H. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nature Rev. Genet. 3, 954-966 (2002).
83. Edwards, D. R. & Murphy, G. Cancer. Proteases - invasion and more. Nature 394, 527-528 (1998).
84. Thurmond, R. L. et al. Identification of a potent and selective noncovalent cathepsin S inhibitor. J. Pharmacol. Exp. Ther. 17, 17 (2003).
85. Saegusa, K. et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Invest. 110, 361-369 (2002).
86. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer; trials and tribulations. Science 295, 2387-2392 (2002).
87. Overall, C. M. & Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2, 657-672 (2002).
88. Weissleder, R., Tung, C. H., Mahmood, U. & Bogdanov, A. Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnol. 17, 375-378 (1999).
89. Callahan, R. J., Bogdanov, A. Jr, Fischman, A. J., Brady, T. J. & Weissleder, R. Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging. Am. J. Roentgenol. 171, 137-143 (1998).
90. Mahmood, U., Tung, C. H., Bogdanov, A. Jr & Weissleder, R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 213, 866-870 (1999).
91. Bremer, C., Tung, C. H., Bogdanov, A. Jr & Weissleder, R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 222, 814-818 (2002).
92. Chen, J. et al. In vivo imaging of proteolytic activity in ahterosclerosis. Circulation 105, 2766-2771 (2002).
93. Tung. C. H., Mahmood, U., Bredow, S. & Weissleder, R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 60, 4953-4958 (2000).
94. Bremer, C., Tung, C. H. & Weissleder, R. In vivo molecular target assessmet of matrix metalloproteinase inhibition. Nature Med. 7, 743-748 (2001).
95. Zucker, S. & Cao, J. Imaging metalloproteinase activity in vivo. Nature Med. 7, 655-656 (2001).
96. Josephson, L., Mahmood, U., Wunderbaldinger, P., Tang, Y. & Weissleder, R. Pan and sentinel lymph node visualization using a near-infrared fluorescent probe. Mol. Imaging 2, 18-23 (2003).
97. Wunderbaldinger, P., Turetschek, K. & Bremer, C. Near-infrared fluorescence imaging of lymph nodes using a new enzyme sensing activatable macromolecular optical probe. Eur. Radiol 13, 2206-2211 (2003).
98. Sameni, M., Moin, K. & Sloane, B. F. Imaging proteolysis by living human breasts cancer cells. Neoplasia 2, 496-504 (2000).
99. Baum, E. Z., Bebernitz, G. A. & Gluzman, Y β-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease. Proc. Natl Acad. Sci. USA 87, 10023-10027 (1990).
100. Block, T. M. & Grafstrom, R. H. Novel bacteriological assay for detection of potential antiviaral agents. Antimicrob. Agents Chemother. 34, 2337-2341 (1990).
101. Tsien, R. Y. The green fluorescent protein. Annu Rev. Biochem. 67, 509-544 (1998).
102. Yuan, J. & Yankner, B. A. Apoptosis in the nervous system. Nature 407, 802-809 (2000).
103. Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
104. Reed, J. C. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. 7, 314-319 (2001).
105. Xu, X. et al. Detection of programmed cell death using fluorescence energy transfer. Nucleic Acids Res. 26, 2034-2035 (1998).
106. van Roessel, P. & Brand, A. H. Imaging into the future: visualizing gene expression and protein interactions with fluorescent proteins. Nature Cell Biol. 4, E15-20 (2002).
107. Rehm, M. et al. Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a process. Role of caspase-3. J. Biol. Chem. 277, 24506-24514 (2002).
108. Onuki, R. et al. Confirmation by FRET in individual living cells of the absence of significant amyloid β-mediated caspase 8 activation. Proc. Natl Acad. Sci. USA 99, 14716-14721 (2002).
109. Harpur, A. G., Wouters, F. S. & Bastiaens, P. I. Imaging FRET between spectrally similar GFP molecules in single cells. Nature Biotechnol. 19, 167-169 (2001).
110. Lee, P., Beem, E. & Segal, M. S. Marker for real-time analysis of caspase activity in intact cells. Biotechniques 33, 1284-1287, 1289-1291 (2002).
111. Hellen, C. U. Assay methods for retroviral proteases. Methods Enzymol 241, 46-58 (1994).
112. Vogt, V. M. Proteolytic processing and particle maturation. Curr. Top. Microbiol. Immunol 214, 95-131 (1996).
113. Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Discov. 2, 624-634 (2003).
114. Molla, A. et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2, 760-766 (1996).
115. Strack, P. R. et al. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc. Natl Acad. Sci. USA 93, 9571-9576 (1996).
116. Shoeman, R. L. et al. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrilary acidic protein. Proc. Natl Acad. Sci. USA 87, 6336-6340 (1990).
117. Lindsten, K., Uhlikova, T., Konvalinka, J., Masucci, M. G. & Dantuma, N. P. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob. Agents Chemother. 45, 2616-2622 (2001).
118. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 26, 186-189 (2003).
119. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763-1767 (2003).
120. Reits, E. A., Griekspoor, A. C. & Neefjes, J. How does TAP pump peptides? Insights from DNA repair and traffic ATPases. Immunol. Today 21, 598-600 (2000).
121. Reits, E. A. & Neefjes, J. J. From fixed to FRAP: measuring protein mobility and activity in living cells. Nature Cell Biol. 3, E145-147 (2001).
122. Dykxhoorn, D. M., Novina, C. D. & Sharp, P. A. Killing the messenger: short RNAs that silence gene expression. Nature Rev. Mol. Cell Biol. 4, 457-467 (2003).
123. Kessler, B. et al. Pathways accessory to proteasomal proteolysis are less efficient in major histocompatibility complex class I antigen production. J. Biol. Chem. 278, 10013-10021 (2003).
124. Föster, T. Zwischenmolekulare energiewandering und fluoreszenz. Annalen Physik. 6, 55-75 (1948).
125. Rudolphi, K., Gerwin, N., Verzil, N., van der Kraan, P. & van den Berg, W. Prainacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11, 738-746 (2003).
126. Whelan, J. Caspase inhibitors for liver disease. Drug Discov. Today 7, 444-445 (2002).
127. Menendez-Arias, L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23, 381-388 (2002).
128. Matz, M. V. et al. Fluorescent proteins from nonbioluminescent Anthozoa species. Nature Biotechnol. 17, 969-973 (1999).